TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03194256

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Spectrum Research Cigarettes
Description: Participants will be assigned to either normal nicotine content cigarettes or very low nicotine content cigarettes.
Study: NCT03866343

Intervention type: OTHER
Group type: OTHER
Intervention: Diet low or high in advanced glycation endproducts
Description: All subjects will undergo an intervention consisting of a prescribed diet containing either a low or high quantity of AGEs during 4 continuous weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet low or high in advanced glycation endproducts
Description: All subjects will undergo an intervention consisting of a prescribed diet containing either a low or high quantity of AGEs during 4 continuous weeks.
Study: NCT03420469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Phase 1: Baseline CYP2D6 activity, using dextromethorphan (30 mg single dose PO) as a probe drug Phase 2: Single dose bupropion pharmacokinetics and its effect on CYP2D6 activity (determined by dextromethorphan 30 mg single dose PO) Phase 3: Steady state disposition of bupropion and its interaction with CYP2D6 activity (30 mg single dose PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Phase 1: Baseline CYP2D6 activity, using dextromethorphan (30 mg single dose PO) as a probe drug Phase 2: Single dose bupropion pharmacokinetics and its effect on CYP2D6 activity (determined by dextromethorphan 30 mg single dose PO) Phase 3: Steady state disposition of bupropion and its interaction with CYP2D6 activity (30 mg single dose PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Phase 1: Baseline CYP2D6 activity, using dextromethorphan (30 mg single dose PO) as a probe drug Phase 2: Single dose bupropion pharmacokinetics and its effect on CYP2D6 activity (determined by dextromethorphan 30 mg single dose PO) Phase 3: Steady state disposition of bupropion and its interaction with CYP2D6 activity (30 mg single dose PO)
Study: NCT02626520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and nanoparticle albumin bound paclitaxel
Description: Gemcitabine and nab-paclitaxel given every 14 days x 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and nanoparticle albumin bound paclitaxel
Description: Gemcitabine and nab-paclitaxel given every 14 days x 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil and irinotecan
Description: FOLFIRI.3 given every 14 days x 4 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation
Description: Pre-operative chemoradiation to 40 Gy in 20 fractions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Definitive resection
Description: Definitive surgical resection of primary tumor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Definitive resection
Description: Definitive surgical resection of primary tumor
Study: NCT02014844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg/m2 aldoxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 350 mg/m2 aldoxorubicin
Study: NCT00407888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT03281928

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium and Potassium Citrate
Description: Sodium and potassium citrate levels will be altered in diet and renal mineral handling will be measured as compared to placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium and Potassium Citrate
Description: Sodium and potassium citrate levels will be altered in diet and renal mineral handling will be measured as compared to placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium without Potassium Citrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium without Potassium Citrate
Study: NCT04364230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6MHP
Description: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NeoAg-mBRAF
Description: BRAF 586-614 (V600E) peptide to which a histidine has been added to the N-terminus, resulting in BRAF 585-614 (V600E).
Study: NCT04520256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss Program
Description: A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.
Study: NCT04364230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PolyICLC
Description: polyICLC, local adjuvant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-1140
Description: CDX-1140, local adjuvant
Study: NCT01934452

Intervention type: DRUG
Intervention: sunitinib
Description: 50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months

Intervention type: DRUG
Intervention: sunitinib
Description: 50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months
Study: NCT03208465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: In empagliflozin group, patients will be prescribed empagliflozin 10mg/day.
Study: NCT03194256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spectrum Research Cigarettes
Description: Participants will be assigned to either normal nicotine content cigarettes or very low nicotine content cigarettes.
Study: NCT01521637

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation of m. quadriceps femoris
Description: Neuromuscular Electrical Stimulation of m. quadriceps femoris by using a commercially available muscle stimulator

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-treatment: no NMES
Description: Sham comparator
Study: NCT03208465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: In sitagliptin group, patients will be prescribed sitagliptin 100mg/day.
Study: NCT03001635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 26 patients will receive Oxytocin infusion for 6h while 26 will receive placebo. all other treatments will be the same and up to date with the current guidelines.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 26 patients will receive 0.9% normal saline infusion for 6h as placebo
Study: NCT03541525

Intervention type: OTHER
Intervention: Biological sampling
Description: Biological samples including blood, surgical remainder, urine,...

Intervention type: OTHER
Intervention: Biological sampling
Description: Biological samples including blood, surgical remainder, urine,...
Study: NCT02276599

Intervention type: PROCEDURE
Intervention: Volume expansion
Description: Fluid bolus of 0.9% normal saline 10 mL/kg over 10 minutes
Study: NCT01218009

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Spiromax
Description: Placebo as a dry-powder inhaled orally using the Spiromax inhaler. During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Spiromax
Description: Albuterol as a dry-powder inhaled orally using the Spiromax inhaler. Each inhalation delivers 90 micrograms (mcg). During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime for a total dose of 720 micrograms per day for those paricipants randomized to the Albuterol treatment arm.~The double-blind period is followed by a 40-week open-label period in which all study participants will take Albuterol Spiromax 90 micrograms (mcg)/inhalation as needed (PRN).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol Spiromax
Description: Albuterol as a dry-powder inhaled orally using the Spiromax inhaler. Each inhalation delivers 90 micrograms (mcg). During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime for a total dose of 720 micrograms per day for those paricipants randomized to the Albuterol treatment arm.~The double-blind period is followed by a 40-week open-label period in which all study participants will take Albuterol Spiromax 90 micrograms (mcg)/inhalation as needed (PRN).
Study: NCT03491540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sennosides colonic preparation
Description: Mechanical bowel preparation :~Sennosides colonic preparation (X-PREP)~1 per day, on day -2 and day -1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sennosides colonic preparation
Description: Mechanical bowel preparation :~Sennosides colonic preparation (X-PREP)~1 per day, on day -2 and day -1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Gentamycin
Description: Oral gentamycin:~Gentamycin 80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Ornidazole
Description: Oral ornidazole :~Ornidazole~1 g per day (2 tablet per day), on day -2 and day -1; In tablets
Study: NCT03378284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan
Description: Tegoprazan QD for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Revaprazan
Description: Revaprazan QD for 7 days
Study: NCT03315676

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Bonoprazan
Description: To examine the efficacy of oral Bonoprazan in patients with NSAIDs-induced Erosions and/or Ulcers

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Esomeprazol
Description: To examine the efficacy of oral Esomeprazol in patients with NSAIDs-induced Erosions and/or Ulcers
Study: NCT01035216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNKG168
Description: GNKG168 will be administered as a 60 minute IV infusion once daily for 5 days followed by a 9 day rest period.
Study: NCT03698370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 DOTA-NeoBOMB1
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 DOTA-NeoBOMB1
Description: Administered intravenously (IV)
Study: NCT03491540

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo Gentamycin
Description: Placebo for oral gentamycin :~Same presentation as oral gentamycin x4 per day on day -2 and day -1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo Ornidazole
Description: Placebo for oral ornidazole :~Same presentation as oral ornidazole~1g per day (2 tablets per day) on day -2 and day -1
Study: NCT03451695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Morphine group will receive intrathecal 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and 100 μg of preservative free morphine (0.1 ml).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group will receive 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and normal saline (0.1ml)
Study: NCT03700554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pleuralvent™
Description: Pneumothorax treatment with Pleuralvent™ device (Heimlich valve device)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chest tube
Description: Chest tube insertion
Study: NCT01253213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR55
Description: One to two bolus (2nd bolus optional) of BR55 per patient
Study: NCT03154775

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-CAR011
Description: Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously at a target dose of 0.5-5.0 x 10\^6 anti-CD19 CAR+ T cells/kg
Study: NCT00109031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palifermin
Description: Administered as one daily intravenous bolus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palifermin
Description: Administered as one daily intravenous bolus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palifermin
Description: Administered as one daily intravenous bolus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: palifermin
Description: Administered as one daily intravenous bolus.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: To be delivered before the administration of chemotherapy in 6, 8, or 10 fractions over 3 or 4 days.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: To be delivered before the administration of chemotherapy in 6, 8, or 10 fractions over 3 or 4 days.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: To be delivered before the administration of chemotherapy in 6, 8, or 10 fractions over 3 or 4 days.
Study: NCT03698370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 PSMA-R2
Description: Administered intravenously (IV)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 PSMA-R2
Description: Administered intravenously (IV)
Study: NCT02005718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Study: NCT00933387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab,Paclitaxel,Cisplatin
Description: Cetuximab 500 mg/m2 iv infusion (120 min for the 1st infusion, 90 min for the 2nd , and 60 min for the subsequent) Paclitaxel 120 mg/m2 3-hour iv infusion Cisplatin 50 mg/m2 2-hour iv infusion
Study: NCT00109031

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total Body Irradiation
Description: To be delivered before the administration of chemotherapy in 6, 8, or 10 fractions over 3 or 4 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is administered at a total dose of 100 mg/kg given in 1 dose on Day -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is administered at a total dose of 100 mg/kg given in 1 dose on Day -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is administered at a total dose of 100 mg/kg given in 1 dose on Day -2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide is administered at a total dose of 100 mg/kg given in 1 dose on Day -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide may be administered (optional) as a single intravenous infusion over 4 hours on the day after the last fTBI fraction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide may be administered (optional) as a single intravenous infusion over 4 hours on the day after the last fTBI fraction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide may be administered (optional) as a single intravenous infusion over 4 hours on the day after the last fTBI fraction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide may be administered (optional) as a single intravenous infusion over 4 hours on the day after the last fTBI fraction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as one daily intravenous bolus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as one daily intravenous bolus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as one daily intravenous bolus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered as one daily intravenous bolus.
Study: NCT02359916

Intervention type: OTHER
Intervention: Time delays on delivery of less healthy snacks

Intervention type: OTHER
Intervention: Time delays on delivery of less healthy snacks

Intervention type: OTHER
Intervention: Time delays on delivery of less healthy snacks

Intervention type: OTHER
Intervention: 25%/$0.25 discount on healthy snacks

Intervention type: OTHER
Intervention: 25%/$0.25 discount on healthy snacks

Intervention type: OTHER
Intervention: 25%/$0.25 tax on less healthy snacks

Intervention type: OTHER
Intervention: 25%/$0.25 tax on less healthy snacks
Study: NCT01360918

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epicardial pulmonary vein isolation
Description: After the CABG procedure, a bilateral epicardial pulmonary vein isolation is performed under general anaesthesia and double-lumen endotracheal ventilation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Management of atrial fibrillation according to current guidelines using rate control pharmacological therapy.
Study: NCT01328496

Intervention type: DRUG
Group type: OTHER
Intervention: Preparative Regimen
Description: Fludarabine (75 mg/m2), fractionated total body irradiation (TBI) (12.0 Gy), and cyclophosphamide (120mg/kg) with mesna. Fludarabine will be given once a day at 25 mg/m2 for three days on day -10 to day -8, TBI will be given twice a day at 150 cGy for four days on day -7 to day -4, and cyclophosphamide will be given once a day for at 60mg/kg for two days on day -3 and day -2.~Post-transplantation immunosuppression with cyclosporine and MMF will begin on day -3. Cord Blood infusion will occur on day 0 and G-CSF will start on day +1.
Study: NCT01744340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Head and neck
Description: Eribulin mesylate is administered by IV infusion over 2-5 minutes on day 1 and 8 of a 21 day cycle 1.4mg/m2 and Cetuximab 400 mg/m2 cycle 1 week 1, then 250 mg/m2/weekly thereafter~Dose Level 1: 0.7 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 2: 1.0 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 3: 1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle
Study: NCT00188305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General health counselling and risk information
Description: General health counselling and risk information

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General health counselling and risk information
Description: General health counselling and risk information

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General health counselling and risk information
Description: General health counselling and risk information
Study: NCT00705159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loteprednol etabonate and tobramycin
Description: Topical ocular administration of loteprednol etabonate and tobramycin 4 times per day (QID) for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: loteprednol etabonate
Description: Topical ocular administration of Lotemax (loteprednol etabonate) QID for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin
Description: Topical ocular administration of Tobramycin QID for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of Zylet
Description: Topical ocular administration of the vehicle of Zylet QID for 14 days.
Study: NCT04864782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1604
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel injection
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/Carboplatin
Description: Intravenous Infusion
Study: NCT03488550

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANX007
Description: Single ascending dose
Study: NCT01918176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib alone
Description: Single dose of 125mg Palbociclib capsule will be administered to subjects orally and then PK samples will be collected at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib + Rabeprazole
Description: Two Rabeprazole 20mg tablets will be given to subjects orally once daily for 7 days. Then on the same day at least 4 hours after the last dose of Rabeprazole, single dose of 125mg Palbociclib capsule will be given to subjects orally then followed by PK samplings at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours.
Study: NCT03710252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin
Description: OMB/PTV/r + DSV +/- RBV
Study: NCT03636854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concentric exercises
Description: Resistance concentric straight leg raise and knee extension will be done.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric exercises
Description: Resistance eccentric straight leg raise and knee extension will be done.
Study: NCT04275960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selitrectinib (BAY2731954)
Description: Selitrectinib is administered orally as liquid suspension (20 mg/mL) on Day 1 of each period. Each period lasts 4 days, both periods of each arm are separated by at least 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selitrectinib (BAY2731954)
Description: Selitrectinib is administered orally as liquid suspension (20 mg/mL) on Day 1 of each period. Each period lasts 4 days, both periods of each arm are separated by at least 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selitrectinib (BAY2731954)
Description: Selitrectinib is administered orally as liquid suspension (20 mg/mL) on Day 1 of each period. Each period lasts 4 days, both periods of each arm are separated by at least 3 days.
Study: NCT01892176

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: coenzyme q10
Description: 400mg/day, 800mg/day, 1200/day and 2400mg/day
Study: NCT01744340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colon- Closed as of May 2014
Description: Eribulin Mesylate:~1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle